clofibric acid has been researched along with HIV Coinfection in 6 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of HIV dyslipidemia should include lifestyle modifications such as a low-fat diet, increased exercise, reduced alcohol consumption and smoking cessation." | 2.43 | Strategies for management and treatment of dyslipidemia in HIV/AIDS. ( Sax, PE, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manfredi, R | 1 |
| Visnegarwala, F | 1 |
| Maldonado, M | 1 |
| Sajja, P | 1 |
| Minihan, JL | 1 |
| Rodriguez-Barradas, MC | 1 |
| Ong, O | 1 |
| Lahart, CJ | 1 |
| Hasan, MQ | 1 |
| Balasubramanyam, A | 1 |
| White, AC | 1 |
| MartÃnez, E | 1 |
| Tuset, M | 1 |
| Milinkovic, A | 1 |
| Miró, JM | 1 |
| Gatell, JM | 1 |
| Fontaine, C | 1 |
| Guiard-Schmid, JB | 1 |
| Slama, L | 1 |
| Essid, A | 1 |
| Lukiana, T | 1 |
| Rondeau, E | 1 |
| Pialoux, G | 1 |
| Sax, PE | 1 |
| Townsend, ML | 1 |
| Hollowell, SB | 1 |
| Bhalodia, J | 1 |
| Wilson, KH | 1 |
| Kaye, KS | 1 |
| Johnson, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of the Safety, Efficacy, and Tolerability of Ezetimibe (Zetia) in Combination With Statin Therapy for the Treatment of Elevated LDL Cholesterol in HIV-Infected Subjects[NCT00099684] | 44 participants (Actual) | Interventional | 2005-11-30 | Completed | |||
| A Pilot Study to Determine the Impact on Dyslipidemia of the Addition of Tenofovir to Stable Background Antiretroviral Therapy in HIV-Infected Subjects[NCT00109603] | 17 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| Myocardial Adipose Inflammation and Pericardial Adipose Volume as Markers for Coronary Artery Disease In HIV Positive Patients[NCT02399384] | 12 participants (Anticipated) | Observational | 2015-01-14 | Completed | |||
| The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers[NCT01148004] | Phase 1 | 25 participants (Actual) | Interventional | 2010-05-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for clofibric acid and HIV Coinfection
| Article | Year |
|---|---|
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Strategies for management and treatment of dyslipidemia in HIV/AIDS.
Topics: Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Clofibric Acid; Drug Interactions; H | 2006 |
4 other studies available for clofibric acid and HIV Coinfection
| Article | Year |
|---|---|
Management of hypertriglyceridaemia caused by combination antiretroviral therapy in HIV-infected patients: role of omega-3 polyunsaturated fatty acids at different dosages, compared with fibrates.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clofibric Acid; Fatty Acids, Omega-3; HIV In | 2010 |
Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Clofibric Acid; Cohort Studies; Female; H | 2004 |
Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
Topics: Anti-HIV Agents; Clofibric Acid; Dideoxynucleosides; Drug Hypersensitivity; Drug Interactions; Drug | 2005 |
A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Cohort Studies; Female; Fish Oils; HIV Infections; Humans; | 2007 |